

SUPPLEMENTAL TABLE 4

NEWLY FDA-APPROVED ANTICANCER THERAPEUTICS: AUGUST 1, 2020-JULY 31, 2021

Approved Indication	Generic Name	Clinical Trial(s)
Angiogenesis Inhibitors		
Certain type of kidney cancer	tivozanib	NCT02627963
Cell-signaling Inhibitors		
Certain type of lung cancer	amivantamab-vmjw†	NCT02609776
Certain type of leukemia*	avapritinib	NCT02561988; NCT03580655
Certain type of non-Hodgkin lymphoma*	crizotinib†	NCT00939770
Bile duct cancer	infigratinib†	NCT02150967
Certain types of lung and thyroid cancers	pralsetinib†	NCT03037385
Certain type of lung cancer	sotorasib†	NCT03600883
Certain type of lung cancer	tepotinib	NCT02864992
Certain types of non-Hodgkin lymphoma	umbralisib	NCT02793583
Cell Cytoskeleton-modifying Agents		
Multiple myeloma	belantamab mafodotin-blmf	NCT03525678
DNA-damaging Agents		
Certain type of gastrointestinal cancers*	fam-trastuzumab deruxtecan-nxki	NCT03329690
Certain type of non-Hodgkin lymphoma	loncastuximab tesirine-lpyl	NCT03589469
Multiple myeloma	melphalan flufenamide	NCT02963493
Certain type of bladder cancer*	sacituzumab govitecan-hziy	NCT03547973
Epigenome-modifying Agents		
Certain type of leukemia*	azacitidine	NCT01757535
Hormones/Antihormones		
Certain type of prostate cancer	relugolix	NCT03085095
Immunotherapeutics		
Certain type of non-Hodgkin lymphoma*	axicabtagene ciloleucel	NCT03105336; NCT02348216
Certain type of skin and lung cancers*	cemiplimab-rwlc†	NCT03088540; NCT03132636
Certain type of endometrial cancer	dostarlimab-gxly†	NCT02715284
Multiple myeloma	idecabtagene vicleucel	NCT03361748
Mesothelioma*	ipilimumab and nivolumab	NCT02899299
Certain type of non-Hodgkin lymphoma	lisocabtagene maraleucel	NCT02631044
Certain type of breast cancer	margetuximab-cmkb	NCT02492711
Neuroblastoma	naxitamab-gqgk	NCT03363373; NCT01757626
Gastric and gastroesophageal junction cancers*	nivolumab	NCT02743494; NCT02872116
Certain types of breast, gastric, and gastroesophageal junction cancers*	pembrolizumab†	NCT02819518; NCT03189719; NCT03615326
Imaging Agents		
Certain type of neuroendocrine tumor	copper Cu 64 dotatate	NCT04334837
Prostate cancer	gallium 68 PSMA-11	NCT0336847; NCT02918357
Prostate cancer	piflutolastat F 18	NCT02981368; NCT03739684
Companion Diagnostic Tests		
Certain type of lung cancer	N/A	NA
Certain types of breast, lung, ovarian, and prostate cancers	N/A	NA
Surgery Guiding Devices		
Osteoid osteoma in the extremities	N/A	NCT02349971
Artificial intelligence-guided assessment for liver cancer	N/A	NCT03213314

*New cancer type approved 2020-2021

†Requires a companion diagnostic